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Abstract  
Introduction In this study, we tested the ability of small molecule inhibitors of WNT/β-
catenin signaling to block IL1β/TNFα induced cartilage degradation. Pro-inflammatory 
cytokines like IL1β and TNFα are potent inducers of cartilage degradation by up-regulating 
MMP expression and activity. Since WNT/β-catenin signaling was found to be involved in 
IL1β/TNFα induced upregulation of MMP activity, we hypothesized that inhibition of 
WNT/β-catenin signaling might block IL1β/TNFα induced cartilage degradation. We tested 
the effect of small molecules that block the interaction between β-catenin and TCF/LEF 
transcription factors on IL1β/TNFα induced cartilage degradation in mouse fetal metatarsals. 
Methods We used mouse fetal metatarsals treated with IL1β and TNFα as an ex vivo model 
for cytokine induced cartilage degradation. Metatarsals were treated with IL1β and TNFα in 
combination with small molecules PKF115-584, PKF118-310 and CGP049090 at different 
concentrations and harvested for histology and gene expression analysis.  
Results We found that IL1β/TNFα induced cartilage degradation in mouse fetal metatarsals 
was blocked by inhibiting WNT/β-catenin signaling using small molecules PKF115-584 and 
partially using CGP049090, dose-dependently. In addition, we found that PKF115-584 
blocked IL1β and TNFα induced MMP mRNA expression, but did not reverse the inhibitory 
effect of IL1β on the expression of cartilage anabolic genes.  
Conclusion In this study, we showed that inhibition of WNT/β-catenin signaling by small 
molecules can effectively prevent IL1β/TNFα induced cartilage degradation, by blocking 
MMP expression and activity. Furthermore, we elucidate the involvement of WNT/β-catenin 
signaling in IL1β/TNFα induced cartilage degradation.  
Keywords: WNT, cartilage, osteoarthritis. 
  
Introduction 
In degenerative cartilage diseases, such as osteoarthritis (OA) or rheumatoid arthritis (RA), 
the balance between anabolic and catabolic processes is shifted towards breakdown of 
extracellular cartilage matrix [1-3]. Cartilage destruction is thought to be the result of 
increased expression and activity of catabolic proteins, such as matrix metalloproteinases 
(MMPs) [4]. Expression of MMP1 (collagenase), MMP3 (stromelysin), MMP9 (gelatinase) 
and MMP13 (collagenase-3) mRNA has been found in chondrocytes in arthritic cartilage [5, 
6]. Increased mRNA expression of MMP1 and MMP3 was also found in the synovial tissue of 
OA patients [7]. In agreement, protein expression of MMP1, MMP3 and MMP9 in the 
synovial fluid of patients with OA in the temporomandibular joint was found to be increased 
compared to healthy control joints [8]. The essential role of MMPs in cartilage degradation 
was illustrated by experimental evidence indicating that MMP13 deficient mice were resistant 
to cartilage damage in medial meniscus destabilization induced cartilage degradation [9]. In 
addition, cartilage degradation induced by IL1β and oncostatin M in human and bovine 
articular cartilage explants could be blocked by a specific MMP13 inhibitor [10].  
Proinflammatory cytokines like interleukin (IL) 1β and tumor necrosis factor (TNF) α 
potently induce MMP expression and activity in cartilage and these cytokines are associated 
with cartilage degradation in vitro and in vivo [6, 11, 12]. The increased expression of several 
MMPs in human articular cartilage explants in similar locations where IL1β and TNFα were 
highly expressed is suggestive for the involvement of IL1β and TNFα in the stimulation of 
MMP expression [11]. In vitro and in vivo studies have shown that proinflammatory 
cytokines, such as IL1β and TNFα are present in both OA and RA joint tissues and synovial 
fluid [1, 4, 13]. IL1β is associated with cartilage degeneration, whereas TNFα was shown to 
be involved in driving inflammation [3]. Besides their role in cartilage degradation by 
  
stimulating MMPs, IL1β and TNFα impair the ability of the cartilage to restore the 
extracellular matrix by blocking the synthesis of new extracellular matrix components [3].  
Recently, the canonical WNT/β-catenin signaling pathway has attracted much attention in the 
pathophysiology of cartilage degenerative disease [14]. The WNT/β-catenin signaling 
pathway is activated upon binding of WNT to its receptor Frizzled (FZD) and coactivator 
LRP5/6. Subsequently, the degradation complex for β-catenin is destabilized, resulting in high 
cytoplasmic levels of β-catenin and translocation of β-catenin to the nucleus where it binds to 
transcription factors TCF and LEF resulting in activation of target genes [15]. Several lines of 
evidence, predominantly derived from animal models, support the involvement of WNT/β-
catenin signaling in the molecular mechanism underlying cartilage degradation. Conditional 
activation of β-catenin in articular chondrocytes in adult mice was found to result in articular 
cartilage destruction with accelerated terminal chondrocyte differentiation [16]. It has also 
been shown that knock-out of FRZB, an antagonist of canonical WNT signaling makes mice 
more susceptible to chemically induced articular cartilage degradation [17]. Furthermore, 
increased expression of secreted Frizzled Related Proteins (sFRPs), which prevent binding of 
WNTs to their receptors, was found in OA synovium, which might be indicative of a 
compensatory mechanism for increased WNT signaling [18].  
Recently, a link between WNT/β-catenin signaling and IL1β-induced cartilage degradation 
was found. Expression of WNT5a and WNT7a in articular chondrocytes was induced by IL1β 
[19] and the combination of IL1β and WNT3a induced greater loss of proteoglycans from the 
extracellular matrix than either alone [12]. In addition, induction of WNT signaling by either 
recombinant WNT3a or GSK3β inhibitor BIO was shown to induce MMP mRNA expression 
and proteolytic activity in mouse cartilage explants. The fact that knockdown of TCF4 
eliminated this effect, indicates the involvement of TCF4 in WNT-induced MMP expression 
  
[20]. In addition, involvement of LEF1 was found in increased MMP13 expression upon IL1β 
stimulation [21].  
Since pro-inflammatory cytokine induced cartilage degradation appears to involve WNT/β-
catenin signaling and increased WNT/β-catenin signaling has been implicated in the initiation 
and progressive deterioration of cartilage degeneration, we hypothesized that small molecule 
inhibitors of the interaction between β-catenin and TCF4 and LEF1 could be used to prevent 
cytokine induced cartilage degradation. The aim of this study is to assess the potential effects 
of small molecules that inhibit the WNT/β-catenin signaling pathway on the degeneration of 
cartilage. We have selected small molecules PKF115-584, PKF118-310 and CGP049090 that 
block the binding of β-catenin to its transcription factor TCF4.  PKF115-584 and CGP049090 
also block the binding between β-catenin and transcription factor LEF1 [22-24]. In addition, 
PKF115-584 not only blocks, but also disrupts the binding between β-catenin and TCF [22-
24]. To study the potential effect of these WNT inhibitors, we used explanted mouse fetal 
metatarsals in which we induced cartilage degradation by adding IL1β and TNFα.  
 
Materials and methods 
Luciferase assay 
HEK293t cells were seeded at 7500 cells/cm2 in 96-wells plates (Nunc International) and 
cultured for 24 hours in DMEM supplemented with 10% FBS and 100 U 
Penicillin/Streptomycin (Gibco), prior to transfection with the TopFlash TCF/LEF luciferase 
reporter construct (Millipore) and pRL-CMV control (Promega). Cells were stimulated with 
the GSK3β inhibitor BIO (Sigma Aldrich) to stimulate the WNT/β-catenin pathway in 
combination with the inhibitors, 24 hours after transfection. After 24 hours of stimulation, 
luminescence was measured using the Dual-Glo luciferase assay (Promega).  
  
 
Metabolic activity 
To study the effect of small molecules on metabolic activity, the pre-osteoblast cell line 
KS483-4C3 was used [25]. Twenty-four hours after seeding, KS483-4C3 cells were 
stimulated with different concentrations of the compounds and 24 hours later, the metabolic 
activity was determined using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. Cells were incubated with MTT for 4 hours and after stopping the 
reaction by adding DMSO, optical density was measured at 540 nm.  
 
Immunofluorescence staining for nuclear accumulation of β-catenin 
Nuclear accumulation of β-catenin was detected by immunofluorescence staining. KS483-
4C3 cells were seeded on glass slides (Nalgene Nunc International) and treated with LiCl both 
with and without small molecule inhibitors. After 3 hours, cells were washed in PBS and 
fixed in 3,7% buffered formalin. Subsequently, cells were quenched in 50 mM NH4Cl for 10 
minutes and incubated overnight at 4oC in NETGEL (50 mM Tris, pH 7.4, 150 mM NaCl, 5 
mM EDTA, 0.05% NP-40, 0.25% gelatin, and 0.02% azide). The next day, cells were 
incubated with anti-β-catenin antibody (1:500 in NETGEL, BD Transduction Laboratories) 
for 1 hour at room temperature. Then cells were incubated with anti-mouse FITC- labeled 
secondary antibody (1:250 in NETGEL, Sigma Aldrich) for 1 hour at room temperature and 
mounted using Vectashield mounting medium (VECTOR Labs). 
 
Mouse fetal metatarsals 
  
Mouse fetal metatarsals were isolated from FVB mouse embryos (time-paired, Harlan) at day 
17,5 of gestation [26, 27]. After isolation, metatarsals were individually cultured in 24-wells 
plates in 200 µl per well in Minimal Essential Medium (MEM) alpha, supplemented with 
10% Fetal Bovine Serum (FBS), 100 U Penicillin/Streptomycin (Gibco) and 1% Glutamax 
(Invitrogen) for 48 hours. After this equilibration period, metatarsals were treated with several 
concentrations of the small molecules either alone or in combination with 10 ng/ml TNFα or 
IL1β (R&D Systems) or a combination of both for 1, 4 or 7 days. Animal experiments were 
approved by the ethical committee of the University Medical Centre Utrecht.  
 
Morphometric and histological analysis 
Optical microscopy was performed at different time points and the lengths of the metatarsals 
were determined along the sagittal axis of the bone, using image analysis software (ImageJ). 
For histological examination, metatarsals were fixed in 10% formalin and dehydrated in 
ethanol series before embedding in paraffin. Five micrometer sections were cut using a rotary 
microtome (HM355S Microm International). Sections were stained for glycosaminoglycans 
using 0,5% Alcian Blue (Sigma Aldrich) in H2O (pH set to 1 using HCl) for 30 minutes and 
counterstained in 1% Nuclear Fast Red (Sigma Aldrich) for 5 minutes. For 
immunohistochemical staining of collagen type II, sections were pre-incubated in 5 µg/ml 
Proteinase K (Sigma Aldrich) for 10 minutes followed by 1 mg/ml Hyaluronidase (Sigma 
Aldrich) for 30 minutes, both at 37oC. Rabbit polyclonal collagen type II primary antibody 
(Abnova) was diluted 1:1000 and incubated overnight at 4oC. For visualization, the 
EnVision®+ System-HRP kit (Dako) was used. 
 
Gene expression analysis 
  
Five metatarsals were pooled and lysed in Trizol for RNA isolation, using the Nucleospin 
RNA II kit (Bioke) according to manufacturer’s protocol. Subsequently, cDNA was 
synthesized using the iScript cDNA synthesis kit (Bio-Rad). Quantitative polymerase chain 
reaction (qPCR) was performed using iQ SYBR Green Supermix (Bio-Rad) on MiQ2 Two-
Color Real-Time PCR Detection System (Bio-Rad). Gene expression was normalized using 
GAPDH and expressed as fold induction compared to controls. Primer sequences are listed in 
table 1. 
 
Statistical analysis 
Results were expressed as mean values +/- 95% confidence intervals (CI) and statistical 
significance was tested using ANOVA (PASW Statistics 18). 
 
Results 
Effect of small molecules on TCF/LEF reporter activity, nuclear translocation of β-catenin 
and metabolic activity 
We first tested the efficacy and specificity of the small molecule compounds to inhibit 
canonical WNT/β-catenin signaling in HEK293t cells transiently transfected with the 
TopFlash TCF/LEF reporter. The compounds were tested in the presence or absence of BIO, a 
potent activator of WNT/β-catenin signaling by blocking GSK3β [28]. We found a dose-
dependent decrease in reporter activity when the cells were treated with BIO and the small 
molecule inhibitors. PKF115-584 treatment resulted in a six-fold decrease in reporter activity 
at a concentration of 1,0 µM. At a concentration of 3,0 µM, luciferase reporter activity 
increased again most likely due to notable cell death upon visual inspection of the cultures. 
  
PKF118-310 and CGP049090 were slightly less effective. Maximal inhibition was found at 
3,0 µM, which decreased reporter activity by four-fold and six-fold respectively (Figure 1A).  
The effect of small molecules on the metabolic activity of cells was tested in KS483-4C3 cells 
using an MTT assay [25]. No significant effects on metabolic activity were found when cells 
were treated with lower concentrations of the compound, however, 1,0 µM or 3,0 µM of 
PKF115-584 and PKF118-310 and 3,0 µM of CGP049090 did cause a significant decrease in 
metabolic activity (Figure 1B). 
Since β-catenin can only effectively activate the WNT/β-catenin pathway after nuclear 
translocation, the cellular localization of β-catenin was determined by immunofluorescence 
staining. Figure 1C shows that stimulation of the WNT/β-catenin pathway by LiCl, which 
also inhibits GSK3β, resulted in translocation and accumulation of β-catenin in the nucleus. 
At 1,0 µM, CGP049090 reduced the intensity of β-catenin staining, but did not inhibit nuclear 
translocation induced by LiCl, whereas PKF118-310 reduced intensity of β-catenin staining 
and also inhibited LiCl induced nuclear translocation. In contrast, PKF115-584 did not affect 
the intensity of the β-catenin staining under basal conditions. In the presence of LiCl, β-
catenin membrane staining was increased but nuclear translocation was markedly inhibited by 
PKF115-584.  
 
TNFα and IL1β induce cartilage degradation in mouse fetal metatarsals 
Metatarsals were cultured in medium containing IL1β or TNFα or a combination of both at 
concentrations of 10 ng/ml. TNFα tended to blunt longitudinal bone growth although this did 
not reach significance. In contrast, IL1β alone induced bone and cartilage resorption resulting 
in a significant reduction in bone length after 4 and 7 days of treatment. Co-treatment of IL1β 
with TNFα caused even more abundant bone and cartilage resorption resulting in a significant 
  
reduction in bone length (Figure 2A/B). Since IL1β and TNFα were more effective than either 
IL1β or TNFα alone, we used the combination of IL1β and TNFα to induce cartilage 
degradation in further experiments.  
 
Inhibitory effect of small molecules on cartilage degradation in mouse fetal metatarsals 
Since visual inspection of cell cultures treated with concentrations higher than 1,0 µM showed 
increased cell death, most likely due to toxic side-effects, we chose to test the effect of the 
three WNT inhibitors in a dose range from 0,1 µM to 1,0 µM. When metatarsals were treated 
with the small molecules only, no effect was observed on the in vitro growth of the 
metatarsals at any of the concentrations that were tested (Supplementary Figure 1). The 
decrease in growth and resorption of the metatarsals when treated with TNFα and IL1β was 
counteracted when metatarsals were treated with small molecules. At a concentration of 1,0 
µM, PKF115-584 blocked bone and cartilage resorption most effectively. Also CGP049090 
counteracted the detrimental effects of TNFα and IL-1β on explant resorption, albeit less 
effective than PKF115-584, whereas PKF118-310 had no significant effect (Figure 3A).  
Alcian Blue staining for glycosaminoglycans demonstrated that the glycosaminoglycan 
content of the cartilaginous matrix of IL1β/TNFα-treated metatarsals was decreased. In line 
with the effect of IL1β and TNFα on glycosaminoglycans in the extracellular matrix, Alcian 
Blue staining was partially preserved by co-treatment with PKF115-584 and PKF118-310, but 
not CGP049090 (Figure 4A/B). Also, Collagen II staining of the extracellular matrix was 
completely lacking after treatment with IL1β and TNFα, whereas co-treatment with PKF115-
584 but not PKF118-310 or CGP049090, could prevent loss of Collagen II from the 
extracellular matrix (Figure 4C).  
 
  
Small molecule WNT/β-catenin inhibitors decrease expression of matrix catabolic genes 
Since the catabolic effect of cytokines on cartilage consists of both induction of MMP 
expression as well as downregulated expression of cartilage matrix genes, we tested the effect 
of small molecule inhibitors on mRNA expression of these genes. In line with previous 
studies [6, 12], IL1β and TNFα significantly induced expression of Mmp3, Mmp9 and 
Mmp13. Small molecule PKF115-584 significantly downregulated IL1β/TNFα induced 
expression of Mmp9 and Mmp13, after 4 days of treatment, whereas CGP049090 only 
blocked the IL1β/TNFα induced upregulation of Mmp9 after 4 days (Figure 5A/B). The 
expression of cartilage matrix genes Acan and Col2a1 was significantly downregulated and 
the expression of Sox9 tended to decrease upon treatment with IL1β and TNFα after 1 and 4 
days of treatment. PKF115-584 and CGP049090 and to a lesser extent PKF118-310 also 
decreased the mRNA expression of Acan and Col2a1 from day 1 on. Neither compound was 
able to counteract IL1β/TNFα induced reduction in gene expression neither at day 1, nor at 
day 4. The three inhibitors did not affect Sox9 nor counteracted the effect of IL1β/TNFα on 
Sox9 expression after 1 day of treatment. Prolonged treatment with small molecules, with the 
exception of PKF118-310, decreased Sox9 expression.  
 
Discussion 
We hypothesized that inhibition of WNT/β-catenin signaling in cartilage might be an effective 
therapeutic strategy for the treatment of cytokine induced cartilage degradation. Therefore, in 
this study we have tested this hypothesis by assessing the effect of recently identified small 
molecule inhibitors of WNT/β-catenin signaling on cartilage degradation in the absence or 
presence of the pro-inflammatory cytokines IL1β and TNFα, which are known to potently 
  
stimulate cartilage degradation by upregulating the expression of MMPs and aggrecanases [1, 
11]. 
Using the TopFlash reporter experiments, we have shown that the small molecule inhibitors 
effectively block WNT/β-catenin signaling, whilst having only a minor unfavorable effect on 
metabolic activity of KS483-4C3 cells at higher concentrations, as measured by MTT assay. 
Immunofluorescence staining for β-catenin revealed that PKF115-584 blocked nuclear 
translocation of β-catenin upon LiCl stimulation, without altering total β-catenin expression in 
basal conditions or after stimulation. PKF118-310 and CGP049090 slightly decreased the 
expression of β-catenin under basal conditions as well as upon LiCl stimulation. PKF118-310 
blocked β-catenin translocation after LiCl stimulation, whereas CGP049090 did not affect 
nuclear translocation of β-catenin. Taking together these findings, we conclude that the small 
molecule inhibitors we selected can be used for further experiments to assess the effect on in 
vitro cartilage degradation. The discrepancy in the effect of the different small molecule 
inhibitors on nuclear translocation of β-catenin, might indicate different mechanisms of action 
between these compounds.  
To study the effects of the compounds on IL1β and TNFα induced cartilage degradation, we 
used an ex vivo model consisting of mouse fetal metatarsals [29, 30]. In degenerative cartilage 
disease, not only chondrocytes, but also osteoblasts in the underlying bone are involved. The 
organ culture system that we used, includes the primary center of ossification and the 
developing bone collar as well as the cartilage template, providing chondrocytes as well as 
osteoblasts. Previously, it has also been shown that in this model system immune cells 
including macrophages and osteoclasts reside in the perichondrium [31]. This allows for 
communication between different cell types implemented in degenerative joint diseases, that 
cannot be mimicked in other in vitro models, such as cartilage explants. Furthermore, in this 
system chondrocytes and osteoblasts are in their natural environment allowing the different 
  
cell types to interact with each other and with the extracellular matrix like they would do in 
vivo. In line with previous studies, we found that IL1β and TNFα are potent inducers of 
cartilage and bone degradation in mouse fetal metatarsals [32-34]. Therefore, we considered 
this model to be suitable for studying the effect of small molecule inhibitors of the WNT/β-
catenin signaling pathway on cartilage degradation induced by proinflammatory cytokines. In 
line with literature, IL1β alone demonstrated a mild effect on explant degradation. TNFα did 
not have an effect but acted synergistically with IL1β [29]. We therefore have chosen the 
combination of these cytokines to induce explant degradation and to evaluate the potential 
effect of the WNT/β-catenin inhibitors. Cartilage degradation is mainly due to increased 
expression and activity of MMPs, which can be induced by, amongst others, IL1β and TNFα 
[1, 11]. Indications of the involvement of WNT/β-catenin in IL1β/TNFα induced upregulation 
of MMPs were found [12]. Based on morphometric and histological examination, we have 
shown that inhibition of WNT/β-catenin signaling by PKF115-584 can prevent the catabolic 
effects of IL1β and TNFα on cartilage. CGP049090 prevented degradation of the extracellular 
matrix as well, albeit less effective, whereas PKF118-310 did not have an anti-catabolic 
effect.  
Gene expression analysis revealed that the compounds, particularly PKF115-584 and 
CGP049090, inhibit IL1β/TNFα induced expression of catabolic genes Mmp3, Mmp9 and 
Mmp13. This indicates that inhibition of WNT/β-catenin signaling has an anti-catabolic effect 
by blocking the induction of MMPs by IL1β and TNFα. In line with previous studies [12], 
this further indicates that WNT/β-catenin signaling is involved in IL1β/TNFα induced MMP 
expression. As mentioned before, the catabolic effect of inflammatory cytokines consists on 
the one hand of the increased expression and activity of matrix degrading proteins, and on the 
other hand of decreased expression of cartilage anabolic genes. For the WNT/β-catenin 
inhibitors to effectively block cartilage degradation, they should interfere with both 
  
components of cartilage destruction. We found that small molecule inhibitors do block the 
catabolic process induced by IL1β and TNFα. However, we did not find an effect of WNT/β-
catenin inhibition on recovery of basal gene expression levels of extracellular matrix 
components Acan and Col2a1 after the use of IL1β/TNFα, indicating that the synthesis of new 
extracellular matrix is not stimulated by small molecule inhibition. In addition, small 
molecules seem to have a repressive effect on bone growth, indicating a combined inhibitory 
effect on differentiation. These findings implicate that WNT/β-catenin signaling is involved in 
the IL1β/TNFα induced effect on catabolic genes, but not in the effect on cartilage anabolic 
genes. In skeletal development, low levels of β-catenin are thought to promote 
chondroprogenitor differentiation, whereas in later stages, high levels of β-catenin promote 
chondrocyte hypertrophic differentiation and subsequent endochondral ossification [35-37]. 
Based on these findings, inhibition of WNT/β-catenin signaling could be expected to induce 
cartilage matrix formation. However, low levels of WNT/β-catenin signaling seem not to have 
a stimulating effect on extracellular matrix formation after IL1β and TNFα induced cartilage 
degradation. Other pathways, such as the MAPK/ERK pathway [38] and the NFκB pathway 
[39], were suggested to regulate the IL1β induced inhibition of gene expression of ACAN and 
COL2A1. Furthermore, immunofluorescence staining of β-catenin indicated that PKF115-584 
might stabilize β-catenin in the cytosol, allowing for β-catenin to exert alternative effects, 
such as direct binding to SOX9 and sequestering of SOX9 in the cytoplasm, thereby inhibiting 
expression of matrix genes.  
Both PKF115-584 and PKF118-310 inhibit WNT/β-catenin signaling by blocking the binding 
of β-catenin to the transcription factor TCF4 [22, Wei, 2010 #118]. We found differential 
effects of PKF115-584 and PKF118-310 on IL1β/TNFα induced cartilage degradation, which 
might be due to the fact that PKF115-584 inhibits translocation of β-catenin to the nucleus 
upon LiCl stimulation without affecting the basal amount of β-catenin, whereas PKF118-310 
  
reduced both. In addition, CGP049090, which blocks the binding of β-catenin to TCF4 and 
LEF1 [24], was not as effective as PKF115-584. This might be due to the fact that PKF115-
584 not only blocks binding of β-catenin to TCF4, but also disrupts binding of TCF4 to DNA 
[24].  
 
Conclusion 
In conclusion, this study provides evidence for the involvement of WNT/β-catenin signaling 
in MMP mediated cartilage degradation induced by IL1β and TNFα. Furthermore, we show 
that WNT/β-catenin signaling is not involved in the repressive effects of IL1β and TNFα on 
cartilage matrix proteins like ACAN and COL2A1. Instead, we provide evidence that 
WNT/β-catenin signaling may be directly involved in the regulation of the expression of these 
extracellular matrix proteins via an as yet unknown mechanism.  
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Figure legends 
Figure 1: Small molecule inhibitors of WNT/β-catenin signaling effectively block TCF/LEF 
mediated activity of β-catenin. A. Small molecules dose-dependently inhibit TCF/LEF 
reporter activity in HEK293t cells, induced by the GSK3β inhibitor BIO (1,0 µM). Data 
represent the mean of three independent experiments +/- CI. B. Metabolic activity, as 
measured using an MTT assay in KS483-4C3 cells, was not affected by small molecules at 
lower concentrations, however, at 1,0 µM (except for CGP049090) and 3,0 µM, metabolic 
activity was significantly decreased. Data represent the mean of three independent 
experiments +/- CI. C. Treatment with 50 mM LiCl induced nuclear translocation of β-
catenin. Small molecules by themselves had no effect on cellular localization of β-catenin, 
whereas PKF118-310 and PKF115-584 blocked LiCl-induced translocation of β-catenin to the 
nucleus. CGP049090 did not affect nuclear accumulation of β-catenin after LiCl treatment. A 
representative example of three independent experiments is shown. Scale bar represents 10 
µm. (* p < 0,05) 
Figure 2: Combined treatment with IL1β and TNFα caused cartilage degradation in mouse 
fetal metatarsals. A. Mouse fetal metatarsals treated with a combination of IL1β and TNFα 
exhibit abundant cartilage resorption, whereas treatment with IL1β alone had minor effects 
and TNFα tended to blunt longitudinal growth only. A representative picture of six 
independent experiments is shown. Scale bar represents 500 µm. B. Treatment with IL1β or a 
combination of IL1β and TNFα significantly decreased bone length after 4 days and after 7 
days of treatment. Data represents the mean of six independent experiments +/- CI. (* p < 
0,05) 
Figure 3: Cartilage degradation induced by IL1β and TNFα in mouse fetal metatarsals can be 
blocked by small molecule WNT inhibitors. A. Morphological changes of metatarsals caused 
by IL1β and TNFα (10 ng/ml each) can be blocked by co-treatment with PKF115-584 at a 
  
concentration of 1,0 µM. CGP049090 partially blocks resorption of the metatarsals, whereas 
PKF118-310 did not have an effect. A representative picture of three independent experiments 
is shown. Scale bar represents 500 µm. B. PKF115-584 dose-dependently blocked a decrease 
in bone length caused by IL1β/TNFα (10 ng/ml each) treatment over time (indicated by red 
arrow). Other compounds and other concentrations did not counteract detrimental effects of 
IL1β/TNFα treatment. Data represents the mean of three independent experiments +/- CI.  
Figure 4: IL1β/TNFα induced loss of glycosaminoglycans and Collagen II was blocked by 
co-treatment with PKF115-584 A. Metatarsals were treated with IL1β and TNFα (10 ng/ml 
each) in combination with small molecule WNT/β-catenin inhibitors (1,0 µM). PKF115-584 
preserved morphology and glycosaminoglycan staining. A representative picture of two 
independent experiments is shown. Scale bar represents 500 µm. B. Magnification of the 
boxed region in A. Scale bar represents 100 µm. C. After 7 days of treatment, PKF115-584 
(1,0 µM) prevented IL1β and TNFα (10 ng/ml each) induced loss of Collagen II staining. A 
representative picture of three independent experiments is shown. Scale bar represents 100 
µm. 
Figure 5: Small molecule inhibitors block IL1β/TNFα induced expression of MMPs, without 
affecting the IL1β/TNFα induced decrease in mRNA expression of cartilage markers. A. 
Significant upregulation of Mmp3 expression was found when metatarsals were treated with 
IL1β and TNFα. Both PKF115-584 and CGP049090 decreased this upregulation after 4 days 
of co-treatment, whereas PKF118-310 did not have an effect. Mmp9 expression was 
significantly downregulated by PKF115-584 after 1 day and IL1β/TNFα induced upregulation 
was prevented by both PKF115-584 and CGP049090, but not by PKF118-310, after 4 days of 
culture. Expression of Mmp13 was significantly upregulated by IL1β and TNFα, whereas this 
effect was blocked by co-treatment with PKF115-584 or CGP049090, but not PKF118-310. 
B. Acan expression is significantly decreased by IL1β and TNFα at both day 1 and day 4. 
  
Also, small molecules PKF115-584 and CGP049090 downregulated expression of Acan by 
themselves. Expression of Col2a1 is downregulated by IL1β and TNFα and this effect could 
not be counteracted by small molecules. No significant effects on Sox9 expression were 
found. Data represents the mean of two independent experiments +/- CI (*p < 0,05). 
Supplemental figure 1: Small molecule inhibitors do not affect mouse fetal metatarsals. A. 
No morphological changes were found in metatarsals treated with small molecules PKF115-
584, PKF118-310 or CGP049090 at a concentration of 1,0 µM. A representative picture of 
two independent experiments is shown. Scale bar represents 500 µm. B. No significant 
differences were found in the bone length when metatarsals were treated with small 
molecules. Data represent the mean +/- C.I. of three independent experiments. 
  
Table 1 Primer sequences for qPCR 
Gene name Primer sequence Product size Annealing temperature 
ACAN For 5' AGGCAGCGTGATCCTTACC 3‘ Rev 5' GGCCTCTCCAGTCTCATTCTC 3' 136 bp 60
oC 
COL2A1 For 5' CGTCCAGATGACCTTCCTACG 3‘ Rev 5' TGAGCAGGGCCTTCTTGAG 3' 122 bp 60
oC 
SOX9 For 5' TGGGCAAGCTCTGGAGACTTC 3‘ Rev 5' ATCCGGGTGGTCCTTCTTGTG 3' 98 bp 60
oC 
MMP3 For 5' TGGCATTCAGTCCCTCTATGG 3‘ Rev 5' AGGACAAAGCAGGATCACAGTT 3' 116 bp 60
oC 
MMP9 For 5' GGTGATTGACGACGCCTTTGC 3‘ Rev 5' CGCGACACCAAACTGGATGAC 3' 115 bp 60
oC 
MMP13 For 5' AAGGAGCATGGCGACTTCT 3‘ Rev 5' TGGCCCAGGAGGAAAAGC 3' 72 bp 60
oC 
GAPDH For 5' CGCTCTCTGCTCCTCCTGTT 3‘ Rev 5' CCATGGTGTCTGAGCGATGT 3' 82 bp 60
oC 
B2M For 5' GACTTGTCTTTCAGCAAGGA 3‘ Rev 5' ACAAAGTCACATGGTTCACA 3' 106 bp 60
oC 
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